Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunity in Low and High-responders After TBE Vaccination
NCT00804219Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Dec 2008
- Primary completion
- Nov 2010
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label trial of FSME-IMMUN in tick-borne encephalitis (TBE) (3 arms), sponsored by Medical University of Vienna. Primary endpoint: Cellular TBE immunity (cytokine production) at 7 days. Started Dec 2008; status: completed.
02
Drugs
FSME-IMMUN
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on NCT00804219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00804219.